Alexion Pharmaceuticals (NASDAQ:ALXN) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $6.60-6.80 for the period, compared to the Thomson Reuters consensus estimate of $7.03. The company issued revenue guidance of $3.85-3.95 billion, compared to the consensus revenue estimate of $4.06 billion.
Several equities analysts have weighed in on the company. Deutsche Bank set a $161.00 target price on Alexion Pharmaceuticals and gave the company a buy rating in a research note on Friday. Citigroup dropped their price target on Alexion Pharmaceuticals from $173.00 to $170.00 and set a buy rating on the stock in a research report on Friday. BidaskClub lowered Alexion Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, February 2nd. Evercore ISI raised Alexion Pharmaceuticals from an in-line rating to an outperform rating in a research report on Monday. Finally, Raymond James Financial reaffirmed an outperform rating and set a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have given a hold rating and twenty-one have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $154.00.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down $0.15 during trading on Friday, reaching $108.32. The company had a trading volume of 363,876 shares, compared to its average volume of 1,984,130. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34. The firm has a market cap of $26,172.44, a price-to-earnings ratio of 48.36, a PEG ratio of 0.98 and a beta of 1.16. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at $4,399,600.36. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP John B. Moriarty sold 3,363 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $115.70, for a total value of $389,099.10. Following the completion of the transaction, the executive vice president now owns 71,400 shares of the company’s stock, valued at $8,260,980. The disclosure for this sale can be found here. In the last three months, insiders sold 28,930 shares of company stock worth $3,378,199. 4.35% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Releases FY18 Earnings Guidance” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.com-unik.info/2018/02/09/alexion-pharmaceuticals-alxn-releases-fy18-earnings-guidance.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.